Kinrix Quadracel – Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Inactivated Poliovirus Vaccine IPV

Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Inactivated Poliovirus Vaccine IPV Brand Names -Kinrix Quadracel

What is Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Inactivated Poliovirus Vaccine IPV

Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Inactivated Poliovirus Vaccine IPV is a combination of 4 vaccines.

It is administered intramuscularly and may be used for the fifth dose in the DTaP and the fourth dose in the IPV immunization series in children 4 to 6 years of age.

Whole cell DTP (DTwP) was previously used in vaccines, but due to the potential association with acute encephalopathy in children, acellular DTP vaccines (DTaP) replaced DTwP in vaccines in the United States.

The administration of combination vaccines such as Kinrix and Quadracel are believed to reduce cost and improve compliance to the recommended vaccination schedule by reducing the number of injections received per physician visit.

The FDA approved Kinrix in June 2008 and Quadracel in March 2015.

Indications

1. diphtheria prophylaxis
2. pertussis prophylaxis
3. poliovirus prophylaxis
4. tetanus prophylaxis

Side Effects

1. anaphylactic shock
2. anaphylactoid reactions
3. angioedema
4. anorexia
5. apnea
6. arthralgia
7. bronchospasm
8. chills
9. cyanosis
10. diarrhea
11. drowsiness
12. dyspnea
13. edema
14. encephalopathy
15. erythema
16. fever
17. Guillain-Barre syndrome
18. headache
19. hypoesthesia
20. hypotension
21. hypotonia
22. inconsolable crying
23. injection site reaction
24. irritability
25. lethargy
26. lymphadenopathy
27. maculopapular rash
28. malaise
29. muscle paralysis
30. myalgia
31. myelitis
32. myocarditis
33. nausea
34. neuritis
35. pallor
36. paresthesias
37. peripheral neuropathy
38. pruritus
39. rash
40. seizures
41. syncope
42. thrombocytopenia
43. urticaria
44. vomiting
45. weakness

Monitoring Parameters

• laboratory monitoring not necessary

Contraindications

• anticoagulant therapy
• breast-feeding
• children
• coagulopathy
• coma
• encephalopathy
• fever
• Guillain-Barre syndrome
• hemophilia
• immunosuppression
• infants
• infection
• intraarterial administration
• intravenous administration
• latex hypersensitivity
• neomycin hypersensitivity
• neonates
• neurological disease
• polymyxin hypersensitivity
• polysorbate 80 hypersensitivity
• pregnancy
• seizure disorder
• seizures
• shock
• subcutaneous administration
• thrombocytopenia
• vitamin K deficiency

Interactions

• Ocrelizumab
• Siponimod